Plain-English translation of NCT06608381 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares two surgical approaches for treating advanced stomach cancer. Both use minimally invasive (laparoscopic) surgery, but they differ in how much of the greater omentum — a protective tissue layer in your abdomen — the surgeon removes. Researchers want to know if keeping part of this tissue (partial removal) works just as well as removing it completely, while potentially reducing surgery time and complications.
Doctors disagree about whether removing all the omentum is necessary during minimally invasive surgery for advanced stomach cancer. Removing the entire tissue takes longer and may increase bleeding and infection risks, but it's unclear whether keeping some of it affects cancer outcomes. This trial will settle that question with solid evidence.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will be randomly assigned to receive either total or partial omentectomy during your minimally invasive gastrectomy surgery. The surgery itself removes the lower portion of your stomach and nearby lymph nodes — the only difference is how much of the protective omentum tissue is removed. After surgery, you will have follow-up visits and monitoring for 3 years to track your recovery and cancer outcomes.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
South Korea